Filing Flows › Companies › Syndax Pharmaceuticals › Timeline
Syndax Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−35.1% to $9.54
Syndax Pharmaceuticals (SNDX) stock fell 35% over the last 252 sessions, to $9.54. On the way it reported 4 quarters, its insiders filed 6 open-market trades and 2 Form 144 notices of planned sales, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 2, 2026 | Earnings | Earnings: missed the EPS estimate by -13.7% | −4.1% (−3.6% vs SPY) | −35.8% (−33.1% vs SPY) | — |
| Oct 29, 2026 | Form 144 | Form 144: Dennis G Podlesak plans to sell $115K | −1.2% (−0.8% vs SPY) | −31.5% (−30.8% vs SPY) | — |
| Aug 4, 2026 | Earnings | Earnings: missed the EPS estimate by -26.0% | −0.8% (−2.6% vs SPY) | +5.7% (+3.7% vs SPY) | +4.4% (+3.8% vs SPY) |
| Jul 8, 2026 | Form 144 | Form 144: Michael Metzger plans to sell $752K | +5.5% (+5.8% vs SPY) | +3.7% (+3.2% vs SPY) | −15.4% (−18.3% vs SPY) |
| Jun 10, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.9% (+0.2% vs SPY) | +8.0% (+5.9% vs SPY) | +26.4% (+22.9% vs SPY) |
| Jun 10, 2026 | 8-K | Material definitive agreement | +1.9% (+0.2% vs SPY) | +8.0% (+5.9% vs SPY) | +26.4% (+22.9% vs SPY) |
| Jun 4, 2026 | 8-K | Material definitive agreement | −1.8% (−2.1% vs SPY) | −4.2% (−0.4% vs SPY) | +18.6% (+18.7% vs SPY) |
| Jun 1, 2026 | Insider sale | Metzger Michael A sold $130K | −3.8% (−4.1% vs SPY) | −12.2% (−9.7% vs SPY) | +11.0% (+12.0% vs SPY) |
| Jun 1, 2026 | Insider sale | Goldan Keith A. sold $22K | −3.8% (−4.1% vs SPY) | −12.2% (−9.7% vs SPY) | +11.0% (+12.0% vs SPY) |
| Apr 30, 2026 | Earnings | Earnings: beat the EPS estimate by 18.8% | +3.8% (+2.8% vs SPY) | +0.1% (−3.0% vs SPY) | −5.2% (−11.3% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: missed the EPS estimate by -34.9% | −0.4% (+0.2% vs SPY) | +4.1% (+5.3% vs SPY) | +17.4% (+24.4% vs SPY) |
| Feb 9, 2026 | Insider sale | Metzger Michael A sold $361K | +0.8% (+0.4% vs SPY) | −2.6% (−1.3% vs SPY) | +14.0% (+15.9% vs SPY) |
| Feb 9, 2026 | Insider sale | Goldan Keith A. sold $72K | +0.8% (+0.4% vs SPY) | −2.6% (−1.3% vs SPY) | +14.0% (+15.9% vs SPY) |
| Feb 6, 2026 | Insider sale | Metzger Michael A sold $153K | +4.2% (+2.3% vs SPY) | +4.8% (+4.3% vs SPY) | +17.0% (+16.9% vs SPY) |
| Feb 6, 2026 | Insider sale | Goldan Keith A. sold $43K | +4.2% (+2.3% vs SPY) | +4.8% (+4.3% vs SPY) | +17.0% (+16.9% vs SPY) |
Insiders’ record here
In the year on the chart, Syndax Pharmaceuticals' insiders reported 0 open-market buys ($0) and 6 sales ($781K). Of the 6 old enough to score, 4 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −4.5%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Syndax Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.